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Abstract
Quantum dots (QDs) possess highly desirable optical properties that make them ideal fluorescent
labels for studying the dynamic behavior of proteins. However, a lack of characterization methods
for reliably determining protein–quantum dot conjugate stoichiometry and functionality has
impeded their widespread use in single-molecule studies. We used atomic force microscopic
(AFM) imaging to demonstrate the 1:1 formation of UvrB–QD conjugates based on an antibody-
sandwich method. We show that an agarose gel-based electrophoresis mobility shift assay and
AFM can be used to evaluate the DNA binding function of UvrB–QD conjugates. Importantly, we
demonstrate that quantum dots can serve as a molecular marker to unambiguously identify the
presence of a labeled protein in AFM images.
In recent years, quantum dot (QD) bioconjugates have become increasingly popular in
fluorescence experiments due to their narrow spectral emission width, strong emission
intensity, small size, and good photostability.1,2 Their strong emission intensities allow
single quantum dots to be visualized by epifluorescence microscopy, while individual
molecules of green fluorescent protein (GFP) and other synthetic fluorophores require the
use of total internal reflection fluorescence (TIRF) microscopy to enhance the signal-to-
noise ratio.3 The unique properties of quantum dots also enable long-term tracking and
monitoring of fast dynamics in single-molecule fluorescence microcopy studies. However,
applications of protein–QD conjugates have so far been limited to antibodies for cell
imaging, Western blot analysis, and fluorescence in situ hybridization.4–8 Enzymatic studies
of proteins using quantum dot conjugates have been limited to only a few proteins such as
myosin, dynein, actin filaments, Rdh54, and Msh2–Msh6.9–14 Several barriers are
commonly encountered when using quantum dot labeled proteins in single-molecule studies.
For example, conjugation of a quantum dot to a protein can potentially interfere with
protein–protein and protein–ligand interactions. In addition, it is possible to conjugate more
than one protein to a single functionalized quantum dot. Although gel electrophoresis in
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combination with Western blotting has been used to quantify the number of antibodies
conjugated to quantum dots,15 this assay provides information on the average properties of
protein–QD conjugates. Information on the population distribution of protein–QD
stoichiometry is needed for single-molecule experiments to ensure accurate interpretation of
the results. Furthermore, methods for reliably assessing the functionality of protein–QD
conjugates, such as their interactions with protein partners and DNA, are still lacking.
Atomic force microscopy (AFM) is a powerful single-molecule technique for studying
biomolecular interactions. This technique can produce topographic images at high resolution
(typically ≥10 nm).16,17 However, for more complex, heteromeric assemblies, which are
ubiquitous in many biological processes, using AFM imaging, we cannot always distinguish
between different types of proteins. This problem could be addressed by incorporating a
specific label on a particular protein. Quantum dots conjugated to a selected protein can
serve as such labels because they form hard spheres (being semiconductor material) and thus
produce much higher topographical signals in AFM than do the more compressible protein
molecules. However, the use of quantum dot labeling in AFM imaging of multiprotein
complexes has not been explored.
In this study, we used the bacterial DNA damage recognition protein UvrB (from Bacillus
caldotenax), which is involved in nucleotide excision repair (NER) as a model to study the
process and effects of protein–QD conjugation. NER can recognize and repair a wide-
spectrum of DNA lesions. In prokaryotes, the NER pathway involves the UvrA, UvrB, and
UvrC proteins.18,19 Although UvrA alone has DNA damage binding specificity, it is
believed that it is the UvrAB complex that allows specific identification of a DNA lesion in
vivo.18,19 Once a DNA lesion is encountered, UvrA hands off DNA to UvrB.20 UvrB then
verifies the damage and recruits the endonuclease UvrC, which carries out incisions on the
damaged DNA strand.21–23
In this report, we use AFM imaging to demonstrate the successful conjugation of single
quantum dots to UvrB. We show that an agarose gel-based electrophoresis mobility shift
assay (EMSA) can be used to evaluate the DNA binding function of UvrB–QD conjugates.
Importantly, in the AFM images of UvrA, UvrB, and DNA, the quantum dot serves as a
molecular marker to unambiguously identify the presence of UvrB on DNA.
Because our approach is easily applicable to the study of other proteins, our results have
broad applications in the fast evolving single-molecule research fields such as fluorescence
and atomic force microscopy. Furthermore, this work will facilitate the development of
protein–QD conjugate-based high-sensitivity molecular machines that utilize the specific
binding properties of proteins and the unique fluorescence properties of quantum dots.
Results and Discussion
Conjugation Approaches
In our first quantum dot conjugation approach, we conjugated UvrB directly to quantum
dots functionalized with succinimidyl trans-4-(maleimidylmethyl)cyclohexane-1-
carboxylate(SMCC). However, the resulting UvrB–QD conjugates showed only minimal
DNA damage recognition activity in the presence of UvrA (data not shown). One possible
interpretation for the drastically reduced DNA binding by UvrB–QD could be that steric
hindrance of the quantum dot occludes UvrB’s ability to interact with either UvrA or DNA.
Another possibility is that thiol modification of UvrB diminishes activity of the protein. To
avoid direct modification of native amino acids on UvrB and increase the spacing between
UvrB and the quantum dot, we developed an antibody sandwich-based conjugation method
(Figure 1). We first added an hemagglutinin (HA) epitope tag (YPYDVPDYA) to the N-
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terminus of UvrB, producing HA-tagged UvrB. A mouse monoclonal HA antibody (Ab)
served as an adaptor for conjugation of the HA-tagged UvrB protein to quantum dots that
were covalently coupled to goat antimouse antibodies. We postulated that the added HA
epitope tag and antibodies would provide sufficient spacing between UvrB and the quantum
dot in the final conjugation product (UvrB–QD) to prevent potential steric hindrance of
protein–protein and protein–DNA interactions posed by the quantum dot.
Using the antibody sandwich linker, we produced conjugates of quantum dots with both WT
UvrB and the domain 4 deletion mutant Δ4 UvrB. We chose Δ4 UvrB mutant conjugate for
analyses because of the greater DNA binding affinities over WT UvrB.24 We previously
showed that domain 4 of UvrB is autoinhibitory as its presence reduces DNA binding and
ATP hydrolysis activities.24 Δ4 UvrB is fully functional in UvrA-dependent DNA damage
recognition. As expected, conjugates of quantum dots to Δ4 UvrB showed higher DNA
binding activity than WT UvrB–QD conjugates in our DNA binding assays (data not
shown). For simplicity, throughout the remaining text and figure legends, we present only
the results on HA-tagged Δ4 UvrB, and we refer to it as UvrB.
Evaluation of Stoichiometry of UvrB–QD Conjugates using AFM
AFM imaging has previously been used to characterize quantum dot size.4 Furthermore,
studies have shown that the volume of a protein molecule measured from AFM images is
directly correlated to its molecular weight (see Supporting Information).17,25 Hence, we
investigated the use of AFM to directly observe binding of UvrB to quantum dots and
quantify the stoichiometry of UvrB–QD conjugates at the single-molecule level. In our
images, a secondary antibody-coated quantum dot exhibits a homogeneous, symmetrical
shape with an AFM volume of 600 (±100) nm3 (Figure 2A). The AFM quantum dot heights
are approximately 4–7 nm. This height measured from our images is smaller than the
diameter of quantum dot conjugates specified by the manufacture (15–20 nm), which
includes the semiconductor core, the core-protecting shell, polymer coating, and surface-
bound antibodies. The smaller AFM heights are not unexpected because this measurement
depends not only on structure of the sample but also on sample–tip and support–tip
interactions.26 In addition, antibody molecules on the quantum dot surface can be
compressed by the imaging process due to forces applied to the sample.27 Consistent with
these ideas, AFM can provide good estimate of the height of the semiconductor core
particle,4 while the average AFM height of biotin–IgG: streptavidin–QD measured from a
previous AFM study is similar to our measurement of the antibody-coated quantum dots.28
After addition of primary HA antibody, AFM images showed small particles in close
proximity to the quantum dots (Figure 2B, purple arrow), indicating binding of HA antibody
to the quantum dots. Statistical analysis of AFM images indicated that 17% (±1%) of the
quantum dots carried these particles. After incubation of quantum dots with preformed
UvrB–Ab complexes, some quantum dots in the AFM images were bound to distinct
particles (Figure 2C, orange arrows) that were larger than the HA antibody alone (Figure
2B, purple arrow). The AFM volumes of these particles were 200–300 nm3, which is
consistent with the combined molecular weights of UvrB and HA antibody. Statistical
analyses of AFM images from multiple sample depositions indicated that with a QD:UvrB–
Ab ratio of 5:1, 19% (±7%) of the quantum dots carried these particles. At QD:protein of
5:1, for both cases with HA antibody alone and UvrB–Ab, the percentages of protein–QD
complexes are close to the expected number (20%). Furthermore, images obtained after
incubation with a higher amount of UvrB–Ab (QD:UvrB–Ab of 1:1) revealed that, under
these conditions, more of the quantum dots (47 ± 9%) carried a UvrB–Ab complex and
approximately 5% of quantum dots showed two UvrB–Ab complexes attached to their
surface (Supporting Information Figure S1). In contrast, with a 5-fold excess of quantum
dots (QD:UvrB–Ab of 5:1), no quantum dots with more than one UvrB–Ab complex in
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close proximity were observed. These results clearly demonstrate that only 1:1 UvrB–QD
conjugates were formed at 5:1 QD:UvrB–Ab (Figure 2C). We therefore used excess
quantum dots (5:1 QD:UvrB–Ab ratio) in all further experiments to prevent multiple UvrBs
from attaching to the secondary antibodies on one quantum dot surface and thus to ensure
preferential formation of 1:1 UvrB–QD conjugates.
As an alternative protein conjugation method, we tried to use biotinylated HA antibodies in
combination with streptavidin-coated quantum dots (Supporting Information Figure S2A,
B). Biotinylated antibodies can be conjugated to streptavidin-coated quantum dots with high
efficiency.15 However, using this strategy, multiple biotins were coupled to each HA
antibody, which allowed the biotinylated HA antibody to act as a bridge between several
streptavidin-coated quantum dots (Supporting Information Figure S2C, D) and led to the
formation of aggregates. Therefore, we do not favor using multiply biotinylated antibodies
for single-molecule studies.
Evaluation of the Interaction between UvrB–QD and UvrA Using AFM
The next step was to ensure that UvrB–QD conjugates are still functional, i.e., they can still
associate with their protein partner, UvrA. In AFM images of UvrB–QD in the presence of
UvrA, some quantum dots were attached to particles (Figure 2D, yellow arrow) that were
bigger than UvrB–Ab complexes (Figure 2C, orange arrows). The additional volume is
consistent with those measured for dimers of free UvrA (approximately 210 kDa) in AFM
images. Statistical analysis of the AFM images indicated that, at a 4:1 ratio of UvrA:UvrB–
Ab, 30 ± 13% of the total protein–QD conjugates (n = 2080) carried additional particles with
sizes consistent with that of a UvrA dimer. In addition, with decreased concentration of
UvrA (UvrA:UvrB–Ab at 1:1), considerably less protein–QD conjugates (10 ± 3%, n = 208)
carried these additional particles. In a negative control experiment using only quantum dots
and UvrA (no UvrB–Ab), colocalization with particles consistent with the size of UvrA was
found only for 1 ± 1% (n = 283) of the quantum dots. These AFM results clearly
demonstrate that UvrB conjugated to a quantum dot can effectively engage UvrA.
Evaluation of the DNA Binding Function of UvrB–QD Using EMSA
To investigate whether or not the UvrB–QD conjugate can still recognize DNA damage, we
developed an agarose-based EMSA. While polyacrylamide offers the advantage of higher
resolution than agarose gels, neither quantum dots alone nor UvrB–QD conjugates could
enter the polyacrylamide gel matrix (unpublished observation). For EMSA experiments, we
used a 50 base pair DNA duplex substrate (1 nM) with a fluorescein adducted thymine at the
central position on the top strand (Figure 3A), UvrA (20 nM), and UvrB (100 nM). Prior
studies have shown that this fluorescein adduct can be recognized as a DNA lesion by the
NER system.20,29 A representative agarose gel and quantification of gels from three
independent experiments are shown in parts B and C of Figure 3, respectively. In the
agarose–EMSA assay, UvrB–DNA complexes (Figure 3B, lane 3) were clearly resolved,
indicating that UvrB was loaded onto damaged DNA by UvrA. In contrast, neither HA
antibody nor quantum dots alone bound to DNA (data not shown). In the presence of UvrA
and preformed UvrB–Ab complexes, greater than 90% of the protein–DNA complexes
afforded a supershift (Figure 3B, lane 4). This shift in complex mobility indicates that
UvrB–Ab was loaded onto damaged DNA by UvrA. Preincubation of UvrB–Ab with the
quantum dots led to a further supershift of the DNA-bound complexes in the presence of
UvrA (Figure 3B, lanes 5 to 8). During electrophoresis in agarose gels, antibody coated-
quantum dots have a distinct slow migration rate. As we increased the amount of quantum
dots (from a ratio of QD:UvrB–Ab 1:1 to 5:1), the majority of UvrB–Ab–DNA complexes
shifted to this slow migrating species, indicating that increases in quantum dot concentration
directly increase the amount of UvrB–Ab–DNA complexed to quantum dots. At QD:UvrB–
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Ab ratios of 2:1 (Figure 3B, lane 7) and 5:1 (Figure 3B, lane 8), the observed UvrB–QD–
DNA complexes represented ~27% and ~46%, respectively, of the total protein–DNA
complexes (Figure 3C). In addition, we did not observe loading of quantum dot-labeled
UvrB onto 50 base pair nondamaged duplex DNA in the presence of UvrA (data not shown).
These results demonstrate that the UvrB–QD conjugate remains functional for DNA damage
recognition and can be loaded specifically onto damaged DNA by UvrA.
Evaluation of Quantum Dot as a Molecular Pointer for AFM Imaging
In AFM imaging of multiprotein–DNA complexes, such as UvrA–UvrB–DNA complexes, it
is often difficult to determine which protein is bound to DNA. Because quantum dots have a
uniform size distribution and are much larger than UvrA or UvrB, we explored the
possibility of using the distinct topographic signals of quantum dots from UvrB–QD
conjugates to pinpoint the presence of UvrB on DNA.
In our AFM study, the DNA–substrate is a 517 base pair PCR fragment (PCR517 DNA)
containing a nick after nucleotide 208 (40%) from the 3′ end (Supporting Information,
Figure S3). Results of prior studies showed that the UvrABC system can carry out incision
of a nicked strand, suggesting that UvrAB recognizes a nick as DNA damage.20,30
Interestingly, we did not observe loading of UvrB onto nicked DNA using EMSA (data not
shown). If UvrB dissociates from a nick during electrophoresis, we would not observe
binding by UvrB to nicked DNA using EMSA. AFM is significantly less sensitive to the
dynamics of the protein–DNA interactions because the deposition of the complexes onto the
mica substrate is rapid and irreversible over the time scale of the depositions.25,31
Consequently, we chose this AFM approach to visualize the UvrB-nicked DNA complexes
that were susceptible to dissociation during electrophoresis.
As a negative control, we first incubated secondary antibody-coated quantum dots with
UvrA and nicked PCR517 DNA. In the AFM images obtained from this sample, the heights
of the quantum dots were larger than 4 nm (Figure 4A, white arrows). Visually, the quantum
dots appeared distinctly different from the UvrA dimers, which were <3 nm in height. This
significant height difference enabled unambiguous distinction between quantum dots and
UvrA. We did not observe UvrA bound to quantum dots in these images, indicating that
UvrA does not nonspecifically bind to secondary antibody-coated quantum dots.
Furthermore, quantum dots were not located on the DNA fragments in the images,
indicating that quantum dots do not bind to DNA nonspecifically. However, our AFM
images did show other particles bound on the DNA (Figure 4A, purple arrows). Greater than
95% of these particles had a volume of 250 ± 28 nm3, which is consistent with the size of
the UvrA dimer (210 kDa). In addition, we observed that decreasing the ratio of UvrA:DNA
by a factor of approximately 6 from 23 to 3.6 nM led to a 57% decrease in the percentage of
DNA fragments that were bound by these particles, which further supports the conclusion
that the particles bound to DNA are molecules of UvrA.
Approximately 45% of the UvrA was bound at DNA ends (for an example, see Figure 4A,
yellow arrow). Given UvrA’s high affinity for ssDNA,32 it is not surprising that UvrA binds
to DNA ends. To obtain the specificity of UvrA for a DNA nick, we excluded the end-bound
UvrA and measured the distances between UvrA and the DNA fragment ends to produce a
statistical position distribution. The position distribution for UvrA on nicked PCR517 DNA
is fit well by a Gaussian curve centered at 40% of the DNA length (Figure 4A, lower panel),
while UvrA was randomly distributed on PCR517 DNA that does not contain a nick
(Supporting Information Figure S4A). A binomial distribution analysis of the position
distribution of UvrA on nicked DNA indicates that the peak at 40% has a P value smaller
than 4 × 10−2. Furthermore, for the position distribution of UvrA on nicked DNA, the
presence of a peak at 40% is independent of bin numbers, further supporting the significance
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of this peak. AFM provides a straightforward method for estimating DNA binding
specificity based on the calculation of the probability of a protein binding to one specific site
divided by the probability of binding to one nonspecific site (see Supporting Information).33
From the numbers of complexes bound at the specific site (the nick, at 40% of the DNA
length) and at nonspecific positions, we calculated that the specificity of UvrA for a nick is
63 ± 19 (n = 110).
As a second control, we incubated UvrA and preformed UvrB–Ab together with the nicked
DNA–substrate. AFM images of this sample also show protein complexes formed on DNA
(Figure 4B, orange arrows), and the position distribution of the complexes on DNA is fit by
a Gaussian curve centered at 39% (Figure 4B, lower panel). A binomial distribution analysis
indicates that the peak at 39% is significant, with P < 7 × 10−5. From the numbers of
complexes bound at the specific site (the nick) and at nonspecific positions, we obtained a
specificity of 118 ± 32 (n = 44) for the nick. In these AFM images, the volumes of the
complexes on DNA were more broadly distributed, ranging from 50 to 500 nm3. This
variation probably reflects a mixture of different complex stoichiometries on DNA. As
discussed above, the different protein types in the complexes cannot be unambiguously
distinguished in the AFM images without a specific marker on one of the proteins.
AFM images obtained after incubation of UvrA and pre-formed UvrB–QD conjugates
together with nicked PCR517 DNA showed DNA-bound particles consistent with the size of
quantum dots (Figure 4C, red arrow). This finding agrees with results from our EMSA
assays (Figure 3) and indicates that UvrA can load UvrB–QD onto DNA. We then evaluated
whether we could unambiguously identify the presence of UvrB–QDs on DNA by
measuring the volume (Figure 5A) and peak height (Figure 5B) of the DNA-bound particles.
The volume distribution is bimodal with peaks centered at ~360 and ~950 nm3 (arrows in
Figure 5A). The first peak centered at 360 nm3 includes volume sizes ranging from 100 to
560 nm3, which are consistent with the predicted AFM volumes of a UvrA dimer
(approximately 240 nm3), UvrB–Ab (200–300 nm3), or UvrA–UvrB–Ab complex (440–540
nm3). The second peak centered at 950 nm3 is quite broad and includes volumes that are
significantly larger than the volume of a quantum dot alone (600 ± 100 nm3). This result
suggests that protein molecules of different stoichiometries (UvrB–Ab and UvrA–UvrB–Ab)
are conjugated to the quantum dots. The measured peak height distribution is also bimodal
with peaks centered at 1.6 and 5.6 nm (arrows in Figure 5B). The height of 1.6 nm is
consistent with that measured from samples containing only unlabeled UvrA and UvrB
proteins. For both the AFM volume and height distributions, the peaks of protein-only and
protein–QD conjugates (arrows in Figure 5A, B) are well separated. These results
demonstrate that the height as well as the volume can be used as primary criteria for the
identification of quantum dots in AFM images. For protein samples, AFM volume is more
reliable in differentiating the size of proteins.25 However, in the case of quantum dots,
which produce much higher topographical signals than proteins due to their lower
compressibility, height may be a better criterion to be used to indentify their presence
(Figure 5). We counted a complex on DNA as a UvrB–QD conjugate-containing complex if
its height was greater than 4 nm and its volume was greater than 600 nm3 (Figure 5). On the
basis of these selection criteria, UvrB–QD conjugates bound to DNA can be identified
unambiguously. It is worth noting that approximately 50% of the UvrB–QD conjugates
bound to DNA were attached to DNA ends, similar to what we observed for UvrA alone.
Again by excluding these end-bound conjugates, we obtained a position distribution
histogram centered at 42% of the nicked DNA length. A binomial distribution analysis
indicates that the peak at 42% is significant, with P < 2 × 10−3. From a Gaussian fit to this
position distribution, we calculated the specificity of the UvrB–QD conjugate for a nick to
be 111 ± 25 (n = 89), which is similar to what was observed in the presence of UvrA and
UvrB–Ab complexes (in the absence of quantum dots). Furthermore, the distribution of
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UvrB–QD on non-nicked PCR517 DNA is not fit well to a Gaussian curve (Supporting
Information Figure S4B). It is worth mentioning that due to the different sizes of UvrA–
UvrB, UvrB, and the quantum dots, UvrB–QD conjugates containing UvrA can be
distinguished from conjugates without UvrA bound. Examples of UvrB–QD and UvrA–
UvrB–QD conjugates on DNA are shown in Figure S5 (Supporting Information).
Comparison of the position distributions for UvrA only, UvrAB complexes (no QDs), and
UvrB–QD conjugates reveals that the center of all three distributions is located at the
specific DNA site (the nick). The results of specificity calculations suggest that the presence
of UvrB increases the specificity for a DNA nick by a factor of approximately two
(specificity of approximately 60 for UvrA versus 110–120 for UvrB and UvrB–QD). AFM
imaging in combination with quantum dot conjugation allowed us to observe the specificity
of UvrB for a nick, which has not been possible when using other biochemical assays. From
analyses in Figure 4 (lower panels), it is worth noting a secondary binding site at 20–25%
from the DNA ends. Most likely, it represents the preference of UvrAB proteins to two A-
tracts (one A7 and one A5) that are present at that region on the PCR517 DNA fragment. It
is known that A-tracts adopt a static bend in the minor groove of DNA,34 which may
enhance UvrAB binding.
Conclusions
In summary, this work demonstrates novel approaches to label a specific protein with a
single quantum dot, identify such labeled proteins, and confirm stoichiometry of protein–QD
conjugates. Importantly, this study establishes AFM and EMSA as complementary methods
to evaluate the extent of protein–QD conjugation, interaction between protein–QD conjugate
and its protein partner, and DNA binding function of the final conjugate. Our results provide
a basis for the development of new protein–QD conjugation strategies for use in single-
molecule studies. We show that quantum dots are highly suitable molecular markers to use
in AFM imaging for identifying the presence of a protein in the context of multiprotein
complexes. Favorable fluorescence properties of quantum dots, such as their broad
excitation spectrum, narrow emission peak, and availability in a wide range of emission
wavelengths, make them an ideal candidate for multiplexing experiments. These properties
and their suitability for visualizing protein–DNA complexes by AFM also open the door to a
combinatory approach using AFM and single-molecule fluorescence microscopy to
unambiguously identify more than one specific protein in multiprotein complexes.
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Strategy used to form UvrB–QD conjugates. An HA epitope tag was added to the N-
terminus of UvrB. A quantum dot coated with secondary antibody was bound to a primary
antibody that recognizes the HA epitope. The UvrB structure was generated from PDB file
1T5L using PdbViewer. Drawings are not to scale.
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Visualization of quantum dots using AFM. AFM surface plots of secondary antibody coated
QDs (A) alone, (B) with HA antibody (purple arrow), (C) with HA antibody and UvrB
(orange arrows), and (D) with UvrB, HA antibody, and UvrA (yellow arrow). The circle in
(D) indicates the part of particle containing UvrA dimer. The AFM image sizes in (A–D) are
300 nm × 300 nm at 10 nm height scale. See Supporting Information for detailed
experimental conditions.
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Testing the DNA binding activity of UvrB–QD conjugates using agarose-based
electrophoretic mobility shift assay (EMSA). (A) DNA–substrate (F50/NDB50) used in
EMSA. The asterisk mark and F symbol represent radioactive labeling and fluorescein
(serving as a DNA lesion), respectively. (B) EMSA assays of UvrA-assisted loading of
UvrB and UvrB–QD conjugates onto the DNA–substrate. (C) Quantification of the
percentage of DNA bound by UvrB–QD conjugates (the bands labeled as “UvrB–QD–
DNA” in Figure 3B). UvrB used in the experiments was HA-tagged Δ4 UvrB and for
simplicity it is referred to as UvrB. See Supporting Information for detailed experimental
conditions.
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AFM images and analyses of complexes formed on nicked PCR517 DNA fragment with (A)
UvrA (purple and yellow arrows) and QDs (white arrow), (B) UvrA/UvrB–Ab (no QD,
orange arrows), and (C) UvrA and UvrB–QD conjugates (red arrow). The top row shows
representative AFM surface plots of the complexes. The images are 500 nm × 500 nm at 10
nm height scale. The bottom row presents the statistical analyses of position distributions of
the complexes observed on DNA, including Gaussian fits to the data (gray lines). The
occurrence probability is the observed probability of proteins or protein–QD conjugates
binding in a given range of positions (see Supporting Information).
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Statistical analyses of volume and peak height of complexes on DNA from AFM images.
Data were collected on nicked PCR517 in the presence of UvrA, UvrB, HA antibody, and
quantum dots. (A) AFM volume distribution. (B) Peak height distribution. The solid and
hatched bars represent complexes that were defined as protein-only and protein–QD
conjugates, respectively. Arrows point to the center (as defined by Gaussian distributions) of
the peaks.
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